Open Access

BRIP1 inhibits the tumorigenic properties of cervical cancer by regulating RhoA GTPase activity

  • Authors:
    • Wei Zou
    • Xiangdong Ma
    • Wei Hua
    • Biliang Chen
    • Yanhong Huang
    • Detang Wang
    • Guoqing Cai
  • View Affiliations

  • Published online on: November 24, 2015     https://doi.org/10.3892/ol.2015.3963
  • Pages: 551-558
  • Copyright: © Zou et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Breast cancer 1, early onset (BRCA1)-interacting protein 1 (BRIP1), a DNA-dependent adenosine triphosphatase and DNA helicase, is required for BRCA‑associated DNA damage repair functions, and may be associated with the tumorigenesis and aggressiveness of various cancers. The present study investigated the expression of BRIP1 in normal cervix tissues and cervical carcinoma via reverse transcription‑quantitative polymerase chain reaction (RT‑qPCR) and immunohistochemistry assays. BRIP1 expression was observed to be reduced in squamous cancer tissue and adenocarcinoma compared with normal cervix tissue, and there were significant correlations between the reduction in BRIP1 expression and unfavorable variables, including the International Federation of Gynecologists and Obstetricians stage and presence of lymph node metastases. In order to elucidate the role of BRIP1 in cervical cancer, a BRIP1 recombinant plasmid was constructed and overexpressed in a cervical cancer cell line (HeLa). The ectopic expression of BRIP1 markedly inhibited the tumorigenic properties of HeLa cells in vitro, as demonstrated by decreased cell growth, invasion and adhesion, and increased cell apoptosis. In addition, it was identified that the inhibitory tumorigenic properties of BRIP1 may be partly attributed to the attenuation of RhoA GTPase activity. The present study provides a novel insight into the essential role of BRIP1 in cervical cancer, and suggests that BRIP1 may be a useful therapeutic target for the treatment of this common malignancy.
View Figures
View References

Related Articles

Journal Cover

January-2016
Volume 11 Issue 1

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Zou W, Ma X, Hua W, Chen B, Huang Y, Wang D and Cai G: BRIP1 inhibits the tumorigenic properties of cervical cancer by regulating RhoA GTPase activity. Oncol Lett 11: 551-558, 2016
APA
Zou, W., Ma, X., Hua, W., Chen, B., Huang, Y., Wang, D., & Cai, G. (2016). BRIP1 inhibits the tumorigenic properties of cervical cancer by regulating RhoA GTPase activity. Oncology Letters, 11, 551-558. https://doi.org/10.3892/ol.2015.3963
MLA
Zou, W., Ma, X., Hua, W., Chen, B., Huang, Y., Wang, D., Cai, G."BRIP1 inhibits the tumorigenic properties of cervical cancer by regulating RhoA GTPase activity". Oncology Letters 11.1 (2016): 551-558.
Chicago
Zou, W., Ma, X., Hua, W., Chen, B., Huang, Y., Wang, D., Cai, G."BRIP1 inhibits the tumorigenic properties of cervical cancer by regulating RhoA GTPase activity". Oncology Letters 11, no. 1 (2016): 551-558. https://doi.org/10.3892/ol.2015.3963